These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 15163596

  • 1. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ, Standaert DG.
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [Abstract] [Full Text] [Related]

  • 2. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
    Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB, Standaert DG.
    Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
    [Abstract] [Full Text] [Related]

  • 3. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E, Riederer P.
    Parkinsonism Relat Disord; 2007 Feb; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
    Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A.
    Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
    [Abstract] [Full Text] [Related]

  • 6. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS, Lipton SA.
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS.
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [Abstract] [Full Text] [Related]

  • 9. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
    Chase TN, Oh JD.
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139
    [Abstract] [Full Text] [Related]

  • 10. Glutamate-based therapeutic approaches: NR2B receptor antagonists.
    Gogas KR.
    Curr Opin Pharmacol; 2006 Feb; 6(1):68-74. PubMed ID: 16376149
    [Abstract] [Full Text] [Related]

  • 11. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL.
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [Abstract] [Full Text] [Related]

  • 12. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G, Abarca J, Bustos V, Riquelme E, Noriega V, Moya C, Campusano J.
    J Neurosci Res; 2009 Aug 01; 87(10):2308-18. PubMed ID: 19326433
    [Abstract] [Full Text] [Related]

  • 13. New targets for pharmacological intervention in the glutamatergic synapse.
    Gardoni F, Di Luca M.
    Eur J Pharmacol; 2006 Sep 01; 545(1):2-10. PubMed ID: 16831414
    [Abstract] [Full Text] [Related]

  • 14. Role of metabotropic glutamate receptors in animal models of Parkinson's disease.
    Senkowska A, Ossowska K.
    Pol J Pharmacol; 2003 Sep 01; 55(6):935-50. PubMed ID: 14730087
    [Abstract] [Full Text] [Related]

  • 15. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ, Jenner P.
    Pharmacol Ther; 2006 Sep 01; 111(3):715-28. PubMed ID: 16458973
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D1 receptors co-distribute with N-methyl-D-aspartic acid type-1 subunits and modulate synaptically-evoked N-methyl-D-aspartic acid currents in rat basolateral amygdala.
    Pickel VM, Colago EE, Mania I, Molosh AI, Rainnie DG.
    Neuroscience; 2006 Oct 27; 142(3):671-90. PubMed ID: 16905271
    [Abstract] [Full Text] [Related]

  • 17. Which factors influence therapeutic decisions in Parkinson's disease?
    Baas H, Fuchs G, Gemende I, Hueber R, Lachenmayer L, Schneider E, Schoenberger B, Werner M.
    J Neurol; 2002 Oct 27; 249 Suppl 3():III/49-52. PubMed ID: 12522573
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM.
    Brain Res Bull; 2009 Feb 16; 78(2-3):85-90. PubMed ID: 18822357
    [Abstract] [Full Text] [Related]

  • 19. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH, Chuang R, Brotchie JM.
    Prog Brain Res; 2008 Feb 16; 172():479-94. PubMed ID: 18772047
    [Abstract] [Full Text] [Related]

  • 20. Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
    Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C.
    Mol Pharmacol; 2006 Mar 16; 69(3):805-12. PubMed ID: 16365282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.